The BCL2L11 Knockout CAL-27 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the CAL-27 human tongue squamous cell carcinoma line with targeted disruption of the BCL2L11 gene. This heterogeneous loss-of-function model facilitates investigation of the pro-apoptotic BH3-only protein BIM while preserving inherent genetic variability, circumventing the bottlenecks of single-cell cloning.
The parental CAL-27 cell line, established from a human tongue squamous cell carcinoma, is a widely employed model for oral squamous cell carcinoma (OSCC) research. It retains key epithelial morphology and oncogenic signaling characteristics, making it an ideal substrate for analyzing oral cancer biology, tumorigenesis, metastasis, and therapeutic responses.
BCL2L11 encodes BIM, a pro-apoptotic BH3-only member of the BCL-2 family that functions as an essential initiator of the intrinsic apoptosis pathway. BIM transcription is controlled by FOXO3A, MYC, and E2F1, and its activity is regulated through phosphorylation by AKT, ERK1/2, and JNK in response to growth factor and cytokine signals, including IL-3 and IL-6. Upon activation, BIM directly binds and neutralizes the anti-apoptotic proteins BCL2, BCL-XL, and MCL1, thereby releasing BAX and BAK to form pores in the mitochondrial outer membrane. This permeabilization event triggers cytochrome c release, promoting APAF1-dependent activation of caspase-9 and subsequent caspase-3 cleavage, ultimately executing cell death. Thus, BIM serves as a critical integrator of multiple survival and stress signals.
In the CAL-27 oral squamous carcinoma context, BCL2L11 disruption impairs the intrinsic apoptotic machinery, mirroring apoptosis evasion mechanisms frequently observed in oral cancers. This knockout model is particularly valuable for investigating chemoresistance, as BIM expression is often diminished in OSCC, contributing to reduced sensitivity to cisplatin and 5-fluorouracil. By eliminating BIM-mediated apoptosis, these polyclonal cells exhibit enhanced survival under cytotoxic stress, enabling dissection of adaptive survival pathways and identification of vulnerabilities targetable by BH3 mimetics or other pro-apoptotic strategies.
This BCL2L11 knockout polyclonal cell population is ideally suited for diverse experimental applications, including mechanistic dissection of apoptosis regulation, screening of BH3 mimetics such as ABT-737 and venetoclax, and evaluation of chemotherapeutic sensitization protocols. Researchers can employ a suite of techniques: Western blotting and RT-qPCR for knockout verification and pathway analysis; Annexin V staining and caspase-3/7 activity assays to quantify apoptosis; mitochondrial membrane potential assays to assess mitochondrial involvement; immunofluorescence for protein localization; and drug sensitivity assays with cisplatin or 5-FU to probe resistance mechanisms. This tool also supports functional genomics and drug discovery programs in OSCC. For further technical information or to discuss customized applications, please contact Ascent Research.
